Want to see CH:MEDX full AI Analyst Report?
Top Page
medmix AG
(MEDX)
Select Model
Select Model
Rating:53Neutral
Price Target:
CHF10.50
▲(17.85% Upside)
Action:Reiterated
Date:08/06/26
Overall score reflects mixed fundamentals with improving but still thin profitability and declining recent revenue, partially supported by positive (though volatile) cash generation. Technicals are moderately supportive near-term but show overbought risk, while valuation is a major drag due to an extremely high P/E and only a modest dividend yield.
Positive Factors
Positive Cash Generation
Positive operating and free cash flow gives medmix internal funding capacity for operations, investment, and shareholder commitments. Although cash generation is volatile, its continued positivity provides a meaningful financial cushion and supports resilience over the next several quarters.
Negative Factors
Declining Revenue
Two consecutive periods of flat-to-declining revenue point to a softer demand backdrop and limit operating leverage. Persistent top-line weakness would constrain medmix’s ability to absorb costs, fund innovation, and convert its specialized market position into sustained earnings growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Positive Cash Generation
Positive operating and free cash flow gives medmix internal funding capacity for operations, investment, and shareholder commitments. Although cash generation is volatile, its continued positivity provides a meaningful financial cushion and supports resilience over the next several quarters.
Read all positive factors
medmix AG (MEDX) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF430.78M
Dividend Yield0.96%
Average Volume (3M)82.95K
Price to Earnings (P/E)4176.0
Beta (1Y)0.96
Revenue Growth-6.64%
EPS GrowthN/A
CountryCH
Employees2,587
SectorGeneral
Sector StrengthN/A
IndustryIndustrial - Machinery
Share Statistics
EPS (TTM)<0.01
Shares Outstanding41,262,370
10 Day Avg. Volume52,900
30 Day Avg. Volume82,953
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)1.08
Price to Sales (P/S)1.02
P/FCF Ratio13.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.52
Revenue Forecast (FY)CHF443.29M
medmix AG Business Overview & Revenue Model
Company Description
Established in 1922 and headquartered in Zug, Switzerland, Medmix AG stands as a global leader in innovating, manufacturing, and distributing high-precision devices and services. These solutions are meticulously engineered for the controlled mixin...
medmix AG Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
58
Neutral
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 437.00M | 448.00M | 483.90M | 486.60M | 477.10M | 457.30M |
| Gross Profit | 160.50M | 161.90M | 159.70M | 157.70M | 175.40M | 181.20M |
| EBITDA | 78.40M | 79.70M | 67.60M | 68.40M | 68.30M | 111.40M |
| Net Income | 100.00K | 6.40M | -7.40M | 300.00K | 11.60M | 44.00M |
Balance Sheet | ||||||
| Total Assets | 970.50M | 969.30M | 954.20M | 1.01B | 1.11B | 974.40M |
| Cash, Cash Equivalents and Short-Term Investments | 111.30M | 113.90M | 96.20M | 130.60M | 316.80M | 210.00M |
| Total Debt | 319.40M | 330.30M | 323.40M | 349.70M | 473.50M | 320.90M |
| Total Liabilities | 537.70M | 536.50M | 507.50M | 532.40M | 601.10M | 440.50M |
| Stockholders Equity | 425.00M | 425.70M | 436.40M | 465.40M | 504.80M | 533.90M |
Cash Flow | ||||||
| Free Cash Flow | 31.70M | 33.30M | 38.10M | 3.20M | 9.00M | 55.40M |
| Operating Cash Flow | 59.30M | 67.80M | 86.60M | 56.10M | 47.60M | 87.30M |
| Investing Cash Flow | -31.70M | -40.70M | -51.50M | -80.60M | -57.00M | -3.30M |
| Financing Cash Flow | -25.80M | -36.30M | -48.60M | -153.80M | 116.10M | 111.60M |
medmix AG Technical Analysis
Positive
8.91
Price Trends
9.44
Positive
8.95
Positive
9.29
Positive
Market Momentum
0.26
Negative
67.82
Neutral
89.87
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:MEDX, the sentiment is Positive. The current price of 8.91 is below the 20-day moving average (MA) of 10.01, below the 50-day MA of 9.44, and below the 200-day MA of 9.29, indicating a bullish trend. The MACD of 0.26 indicates Negative momentum. The RSI at 67.82 is Neutral, neither overbought nor oversold. The STOCH value of 89.87 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:MEDX.
medmix AG Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | CHF248.08M | 9.02 | 11.74% | 3.96% | -1.24% | -11.13% | |
69 Neutral | CHF194.07M | 13.47 | ― | 2.80% | -2.82% | ― | |
67 Neutral | CHF5.88B | 19.41 | 23.26% | 2.73% | -2.55% | 11.09% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | CHF393.27M | -41.91 | ― | 1.89% | -2.66% | 9.28% | |
54 Neutral | CHF4.70B | -34.91 | ― | 2.36% | -20.47% | -148.37% | |
53 Neutral | CHF430.78M | 4,176.00 | ― | 0.96% | -6.64% | ― |
* General Sector Average
CH:MEDX
medmix AG
10.44
0.88
9.17%
CH:GF
Georg Fischer AG
57.25
1.35
2.41%
CH:KOMN
Komax Holding AG
76.70
8.90
13.13%
CH:MIKN
Mikron Holding AG
15.15
-5.38
-26.19%
CH:SUN
Sulzer AG
174.10
43.10
32.90%
CH:STGN
StarragTornos Group AG
35.70
5.22
17.13%
medmix AG Corporate Events
Medmix launches eco-efficient MIXPAC PiccoMix tip for dental cementation
Oct 15, 2026
Medmix AG has expanded its dental portfolio with the launch of the MIXPAC PiccoMix mixing tip, a next-generation device for dental cementation designed to improve efficiency and sustainability in material delivery. Targeting growing demand driven ...
medmix Earns Second Straight CDP “A” for Climate-Focused Supplier Engagement
Sep 15, 2026
medmix has secured an “A” rating in CDP’s Supplier Engagement Assessment for the second consecutive year, placing it among a small group of global leaders recognized for actively managing climate-related risks across their supply...
Medmix Teams with Xeris to Power Precise Delivery of New Hypothyroidism Therapy
Sep 10, 2026
Medmix’ Drug Delivery unit Haselmeier has entered a collaboration with Xeris Pharmaceuticals to support the development of XP-8121, an investigational once-weekly subcutaneous levothyroxine therapy for hypothyroidism. The partnership centers...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.